In-vitro proteinase production by oral Candida afbicans isolates from patients with and without HIV infection (18 isolates from each group) was assessed by image analysis of a plate assay, with bovine serum albumin (BSA) as a substrate. The effect of subminimal inhibitory concentrations (sub-MICs) of nystatin, amphotericin B, clotrimazole and miconazole on in-vitro proteinase production by these yeast isolates was also investigated. Proteinase production by C. albicans isolates from patients with HIV infection was significantly greater than production by those from individuals without infection. All 18 isolates from HIV-infected individuals produced proteinase, in comparison to 56% of isolates from uninfected individuals. Pre-exposure of C. albicans isolates (seven proteinase producers from each group) to 1/4 and 1/16 MICs of nystatin, amphotericin B, clotrimazole and miconazole resulted in decreased proteinase production in all isolates tested. However, after exposure to the four antimycotic agents, proteinase production was decreased to a significantly greater extent in isolates from uninfected individuals than in those with HIV disease. Furthermore, when the relative concentration effect of antimycotic agents on proteinase production was compared, C. albicans isolates from the HIV-free group demonstrated a salient dose-response relationship compared with the HIV-infected group. These results indicate that C. albicans from patients with HIV infection are significantly more proteolytic than those from individuals without the infection, and that polyenes and imidazoles curtail the proteolytic activity of all C. afbicans isolates, albeit to a lesser extent in those from HIVinfected patients. It appears that HIV disease favours oral colonisation by more proteolytic C. afbicans isolates, with resilient proteolytic activity.
Introduction
Extracellular proteinase is considered to be a virulence factor of C. albicans [l-31, the most common agent of human candidosis. For example, immunoglobulin A, one of the main mucosal defence barriers, can be rapidly and thoroughly cleaved by proteinase [4] . It has also been reported recently that complement C3 and some specific endogenous proteinase inhibitors involved in regulating inflammation can also be degraded by C. albicans proteinase [5] . Proteinase of C. albicans can digest, in vitro, several physiologically important substances including albumin, keratin and skin proteins [3, 6, 7] . The in-vivo secretion of proteinase has been demonstrated in infected tissues by histochemical methods [8, 9] ; moreover, secretion of proteinase correlates strongly with other virulence traits of C. albicans, such as adherence to epithelia [lo] . The foregoing suggest the importance o f Candida proteinase in the pathogenesis of candidosis.
The extracellular proteinase of C. albicans, first described by Staib [l 13, is not a single entity but is known to consist of three distinct enzymes [4] , a complete proteinase and two that are partially proteolytic. Although the latter enzymes differ from the complete proteinase in substrate specificity and other properties, they cross-react immunologically with each other. These enzymes are classified as aspartate proteinases (EC 3.4.23.6) and are related to pepsin, renin and cathepsin D. Their mol.wt is c. 45 kDa, with optimal activity in the pH range 3.5-4.0 [12] .
It is recognised that oral candidosis caused by C. albicans is one of the most common infections associated with human immunodeficiency virus (HIV) infection [13, 141. Nevertheless, little is known of the production profile of the extracellular proteinase of C. albicans from HIV-infected patients in comparison with those from disease-free individuals. Very recently it has been observed that some isolates of C. albicans from HIV-infected patients are more proteolytic than those from HIV-uninfected individuals [ 1 5 , 1 61.
Furthermore, the effect of major antimycotic agentspolyenes and imidazoles -on in-vitro proteinase production by C. albicans has not been studied systematically. Angiolella et al. [ 171 investigated this phenomenon and noted that methyl partricin, fenticonazole and 5-fluorocytosine suppressed proteinase production by C. albicans, but no other reports of this phenomenon are documented.
by Staib [ll] . Briefly, an 18-h yeast suspension of 1 X lo6 celldm1 was prepared, and 5 pl of this yeast suspension were s@ inoculated on to a BSA 1% agar plate. The plate wtts incubated aerobicdy in a humidified container for 5 days at 37"C, flooded with naphthalene black 1 -25% solution in methanol/water 90% v/v for 15 mh and decolourised for a hrther 36 h with several c h a w of the latter solution. Tihe diameter of the zone proteolysis and the m l m y wem examined and quantified by Quantimet 580+ I m g e Analysis System (Quantimet Image System, Leica Instruments, Hong Kong). Proteinase production ( R a value) was calculated as follows:
(where D, was the diameter of the zone of protealpis and the colony, D,, was the diameter ofathe colony). Accordingly, two related investigations were performed in the current study, with two groups of 18 oral isolates of C. albicans, from patients with and without HIV infection. Firstly, in-vitro proteinase production by oral
All the experiments were repeated on three separate occasions with duplicate determinations .on each occasion.
C. albicans isolates from these two groups was compared, and secondly, the effect of antimycotic agents
Preparation of antimycotic agents
on proteinase secretion of a randomly selected group of Antimycotic agents used were as follows: nystatin, 14 isolates was assayed by exposing them to 1/4 and 1/ amphotericin B, clotrimazole and miconazole (Sigma). 16 sub-MICs of two polyenes (nystatin and amphoNystatin and amphotericin B were dissolved in a tericin B) and two imadazoles (clotrimazole and .mixture of dimethyl sulphoxide and ethanol (3:2); miconazole). isolates was fkm HIV-he patients with angukr cheilitis, obtained by the Microbiology Research Services of the m e institution These isolates were identified by sugar assimilation and fermemtation tests with the API 20C system (API products, bioMerieux, Lyon, France) and the 'gem tube' test. Stock cultures were maintained at 4°C on Sabouraud dextrose agar (SDA). All isolates were first screened for proteinase production by the bovine serum albumin (BSA) assay; proteinase-positive isolates (seven from each group) were subsequently selected at random for tests with antimycotic agents.
' M a t e a s and rnei&&s

Candidi isolates arrd growth cmditions
To tttest the effect $of antimycotic agents on proteiprodbation by C. a&oc?ns, a loogful d 18-h yeast grow& was transfmed b 10 ml of yeatiit nitrogen base m e d i m supplemented with 5 0 m~ glucose with or w i t h m tubinhibitory concentrations of l/U and 1/16 MIC diI&ns of antimycdcs, and grown aerobically at 37°C in a shaking water bath for 18 h. The cells were harvested by centrifuging at 1500 g for 10 min, washed twice in 19 ml of sterile phosphate-buffered saline (0.1 M, pH 7.2) and resuspended in the same buffer to a final concentration of 1.0 X lo6 yeastdm1 as determined by microscopic counting in a haemocytometer counting chamber. The subsequent procedure for inducing proteinase production on BSA was as described above.
Quantification of proteinase production by the BSA assay Statistical analysis
Extracellular proteinase production by C. albicans was induced with BSA according to the technique described
All the numerical data obtained were analysed by the Wilcoxon matched-pairs signed-ranks test.
Results
Assessment of proteinase activity by the image analysis system
In pilot studies both visual and computerised image analysis measurement were used to record the diameter o€ the zone of p-oteolysis and the h g a l colony. As highly concordant and accurate results were obtained once the image analysis system was standardised, the latter was used subsequently throughout the study. The replicate Pcd data for each isolate were highly .reproduci"bSle, as shown by the very low standard deviation ( m g e 0.0-8.4'36); ?he highest coefficknt of variatim <9%.
In-vim proteinase pmt&w.tiun by C. olbicans isolates from patients with and w h u t HIV in fedtion C. aybicans isolates from HIV-infecetsd patients were significantly more proteolytic than those from HIVuninfected individuals (p = 0.002, Fig. I ). The mean Prd value for the HIV group (1.73) was 25% higher than that for the HIV-free group (1.29). It was also noticeable that all 18 isolates in the former group were proteinase positive, in contrast to 56% isolates in h e latter group.
Effect of antimycotic agents on in-vitro proteinase production
The effect of four different antimycotic agents on proteinase production of C. albicans from individuals with or without HIV infection is shown in Fig. 2 . Compared with the control groups (no antimycotic treatment) exposure to sub MICs of nystatin, amphotericin B, clotrimazole and miconazole significantly decreased proteinase production by all 14 C. albicans isolates tested (p = 0.008; Fig. 2, right-hand column) . Of the four antirmycotic agents tested, exposure to subMICs of miconazole result4 in the greatest reduction in proteinase groduction (22.3 5%), followed by nystatin (2 1.18%), amphotericin B (1 6.47%) and clotrimazole (15.88%).
When the effect of antimycotic agents on isolates from the HIV-infected and non-infected groups was compared, it was clear that proteinase production was reduced to a significantly greater extent in the isolates from the latter group (except exposure to 1/16 MIC of nystatin) (Table 1) .
Generally, there was a good dose-response relationship between enzyme production and exposure to all four antimycotic agents in isolates from the disease-free group, i.e., exposure to 1/4 MIC suppressed proteinase production to a greater extent than exposure to 1/16 MIC (p < 0.01, Fig. 3 ). However, this phenomenon was less apparent in the isolates from the HIV group exposed to nystatin and clotrimazole. There was no significant difference in proteinase production between 114 and 1/16 MICs exposure of isolates to the two drugs (p > 0.05, Fig. 3 ). Candida infections are found in at least 80% of patients with acquired immunodeficiency syndrome (AIDS) and in about one third of those with HIV infection [13, 14, 191 . Oral candidosis is one of the most common fungal infections, appearing mainly in the oral cavity as erythematous or pseudomembranous lesions [ 1 3,141. C. albicans is undoubtedly the most common causative agent of this disease; its extracellular acid proteinase is a recognised virulence attribute, which facilitates tissue penetration, while proteinase-deficient strains are less invasive [3] . Whereas some have cast doubt on the relevance of candida proteinases in oral candidosis [20] , others have demonstrated convincingly that conditions may prevail intra-orally that facilitate its activity [2 1,221. Indeed, the acidic proteinase of C. albicans, which requires low pH for optimal activity, is active in acidic salivas that persist in certain physiological and pathological states (e.g., xerostomia, Sjogrens syndrome) [23] . Interestingly, xerostomia and accompanying changes in salivary composition and lower pH The results of the effect of polyenes (nystatin and amphotericin B) and imidazoles (clotrimazole and miconazole) on extracellular proteinase of C. albicans from individuals with and without HIV infection indicate that sub-MICs of these antifungal agents may modulate the proteolytic activity of C. albicans. This conclusion differs from that of the report by Angiolella et al.
Discussion
[ 171. They found that only the polyene derivative methyl partricin suppressed proteinase production, but not the azoles miconazole, fluconazole and ketoconazole. This disparity is likely to be due to the fact that only a single isolate was used by the latter workers; 14 isolates were used in the current study.
The present results indicate that exposure to polyenes and imidazoles tends to have less inhibitory effect on proteinase production by C. albicans isolates from patients with HIV infection, when compared with isolates from patients without HIV infection. This suggests that proteinase production in C. albicans isolates in HIV disease is not only stronger but also more recalcitrant than in isolates from uninfected groups. Indeed, genetically atypical C. albicans isolates less susceptible to antimycotic agents have been described in HIV-infected patients [ 171, indicating that response to antifungal agents may be modulated in association with HIV disease. In clinical terms, this sequence of events might then be one reason for the well known treatment failure of oral and systemic antimycotic therapy of oral candidosis in HIV-infected and AIDS patients [14, 29] .
